Purchase Order 75N91024P00111
Award Date
12/1/23
Potential Completion Date
1/17/24
Potential Value
$23K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
811310 - Commercial and Industrial Machinery and Equipment (except Automotive and Electronic) Repair and Maintenance
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20852, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order valued at eleven thousand nine hundred eighteen dollars and thirty-four cents ($11,918.34) to Illumina, Inc. to provide a NextSeq 2000 Silver Support Plan for the period of November 2, 2023 through January 31, 2024. The support plan is for a NextSeq 2000 sequencer located at the National Cancer Institute in Bethesda, Maryland and will maintain...
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $130,847 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The purpose is to procure preventive maintenance services for a government-owned Illumina NovaSeq 6000 Sequencing System located at the National Cancer Institute in Bethesda, Maryland. The Laboratory of Pathology requires these services to maintain optimal instrument operation, generate comparable...
The Department of Health and Human Services National Institutes of Health Office of Logistics and Acquisition Operations awarded a $906,270 purchase order to Illumina, Inc. to supply and install a NovaSeq 6000 sequencing system. The place of performance is in Bethesda, Maryland. The firm fixed price contract has a period of performance starting on July 7, 2020 and ending on August 31, 2020. The National Institutes of Health will utilize the new sequencing system in support of its biomedical...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomics sequencing systems and reagents, for the procurement of an Illumina NextSeq 550 sequencing system. The $266,475 award was made on May 24, 2019 with an August 22, 2019 completion date. This purchase will complement the NCI's existing Illumina NextSeq 500 and MiSeq instruments used by...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing systems and solutions, for preventive maintenance, emergency service, and support for a government-owned Illumina NovaSeq 6000 Sequencing System. The contract has a period of performance from August 1, 2022 to July 31, 2023 and a potential value of $119,523.28. The requirement was...
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $238,017.50 firm fixed price purchase order to Illumina, Inc. for the acquisition of an Illumina NextSeq 2000 sequencing system. The award did not include any set-aside designation. The sequencing system will support the National Cancer Institute's Surgery Branch in developing novel immunotherapies for the treatment of various cancers, including melanoma, gastrointestinal, lung, and...
This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc. for $83,322.00. The contract provides for preventive maintenance, emergency service, support, and coverage for a government-owned Illumina NovaSeq 6000 sequencing system to support NCI's Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) clinical...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $20,381.70 firm fixed price purchase order to Illumina, Inc. for unspecified products or services. The place of performance will be in Bethesda, Maryland through September 2023. Illumina will deliver the requested items or work to support the National Cancer Institute, part of the NIH focused on cancer research, treatment, and initiatives to reduce the public health burden of cancer....
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Purchase Order 20019983 to Illumina, Inc. for $15,575. The order is for an MISEQ Silver Support Plan (SV-420-1003) to be performed at the prime contractor's facility in Bethesda, Maryland from August 1, 2023 through July 31, 2024. The firm fixed price contract provides support services for the MISEQ sequencing system serial number M01303 in support of the NIH National Cancer Institute's...